Key result
Selexipag is an oral selective prostacyclin receptor agonist developed to target the pathophysiological mechanisms of pulmonary arterial hypertension.
Selexipag is an oral selective prostacyclin receptor agonist developed for the treatment of pulmonary arterial hypertension.
Supports targeted PAH therapy development; leaves open rigorous outcome validation in clinical practice.
Pulmonary arterial hypertension (PAH) is a rare disease which is characterized by the progressive increase of pulmonary arterial pressure. PAH can lead to right cardiac insufficiency and death. Conventional and other treatment modalities that target the physiopathological and etiopathological causes of the disease are currently being used. Selexipag is an oral selective prostacyclin receptor agonist which was developed to overcome the pathophysiological mechanisms that play role in the PAH.
No takes yet. Share an insight, caveat, or question.
Yazıcı et al. (2019) conducted a review in Pulmonary arterial hypertension (PAH). Selexipag was evaluated. Selexipag is an oral selective prostacyclin receptor agonist developed to target the pathophysiological mechanisms of pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: